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INTRODUCTION
Diffuse Intrinsic Pontine Glioma (DIPG) remains a leading
cause of death for children with brain tumors. DIPG is unresectable
because of its location and infiltrative nature. The role of biopsy for
patients with DIPG has been controversial [1–4]. In 1993, Albright
reported the results of the Children’s Cancer Group (CCG) 9882
DIPG study and concluded that magnetic resonance imaging (MRI)
was adequate in making the diagnosis, and tissue diagnosis did not
alter the treatment nor did it impact outcome [1]. Based on this
conclusion and the presumed risk of surgical complications, tumor
biopsy has been rarely performed.
There has been no improvement in the outcome for patients with
DIPG in the past 30 years despite decades of clinical trials. The lack
of primary tumor materials from not performing biopsy had made
preclinical research difficult and hindered the development of
new therapies. An effort has been made to acquire post mortem
samples [5–8]. While the information generated from autopsy
materials has been very helpful in confirming the clinical diagnosis
and understanding tumor biology, it is often confounded by the
effect of prior radiation treatment and limited by the difficulty in
collecting tissues in a timely fashion. In addition, DIPG at diagnosis
may be molecularly distinct from that identified at the time of
autopsy [8]. While the necessity for tumor tissue at diagnosis has
been increasingly recognized, the morbidity associated with the
biopsy is not well defined due to the rarity of this procedure
performed, so the debate on whether to perform a biopsy upfront
continues [1,2,4]. The aim of this study was to retrospectively
review our experience of surgical biopsy of DIPG.
METHODS
Twenty-two consecutive cases of DIPG diagnosed and treated
from 2001 to 2012 at the Children’s Hospital of Michigan (CHM)
were identified from the institutional database and reviewed
retrospectively. Because of the small number of cases, all statistics
are descriptive. This project was approved by the Human
Investigation Committee of Wayne State University.
RESULTS
Among the 22 cases with a diagnosis of DIPG, 12 were males
and 10 were females. The age at presentation ranged from
20 months to 16 years. Risks of procedure were discussed with
patient’s guardian prior to the procedure, and a biopsy was
performed on 15 of those 22 cases. The characteristics and
outcomes of these 15 cases are summarized in Table I.
All patients underwent a stealth guided stereotactic biopsy of the
lesion using a posterior fossa transcerebellar peduncle approach.
Biopsies were done using Medtronic Biopsy Needle Kit1
(Medtronic Navigation Inc, 826 Coal Creek Circle, Louisville,
CO 80027) under stereotactic guidance. Dexamethasone was
started prior to or right after surgery on all patients. No intra-
operative complications or surgery-related mortality was observed,
and no permanent deficits were noted. Transient new or worsening
neurological deficits were recorded in three of 15 patients. Case 11
presented with a history of ataxia and cranial nerve palsy with MRI
findings typical of DIPG (Fig. 1A). Her symptoms worsened
following a biopsy, but started to improve two weeks after starting
radiation therapy and completely resolved at the completion of
treatment, with significant reduction in size of the tumor in the
follow up MRI (Fig. 1B). A transient increase in weakness of the
lower extremities and worsening of speech was observed in Case
13, and a transient left facial palsy was recorded in Case 14.
All biopsies were successful, in that adequate tumor tissue was
collected for histopathological diagnosis and immunohistochemi-
cal (IHC) staining. All patients had astrocytoma. Thirteen had high-
grade astrocytoma and two patients had a low-grade astrocytoma.
IHC staining for p53 and epidermal growth factor receptor (EGFR)
was performed in eight cases and was positive in six cases for each
marker (Table I).
As for the treatment and outcome, Case 5 received supportive
care only, and Case 14 was transferred to another center following
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diagnosis. All other patients received involved-field external beam
radiation and several patients received chemotherapy. All patients
died of disease progression with a mean overall survival of
10.4 3.8 months. The Case 1 was a 4-year-old female who
presented with a history of ataxia, cranial nerve palsy, and lower
extremity weakness for 5 days with a MRI findings typical of DIPG
(Fig. 1C). Tumor histologywas consistent with grade I astrocytoma.
She responded to radiation therapy initially with improvement of
TABLE I. DIPG Case Summary
Age







1 4 F ataxia, left facial & 6th nerve palsy,
right extremity weakness
No I 10 N/A N/A
2 3 F ataxia, right facial palsy, slurred speech No II 9 N/A N/A
3 13 M headache, diplopia No III 7 N/A N/A
4 12 M ataxia, slurred speech, right extremity weakness No III 8 N/A N/A
5 4 M headache, ataxia, vomiting No III 4 positive positive
6 7 M ataxia, 6th nerve palsy No IV 18 N/A N/A
7 9 M ataxia No III 13 positive positive
8 16 M incidental finding followed by headache No IV 9 negative positive
9 14 M ataxia, slurred speech No III 10 positive negative
10 9 F ataxia, headache, vomiting No III 16 negative positive
11 4 F ataxia, left facial palsy, slurred speech Yes IV 12 positive positive
12 7 M ataxia, right facial palsy, left extremity weakness No IV 9 positive negative
13 7 F ataxia, ptosis, slurred speech Yes III 7 N/A N/A
14 15 M headache Yes IV N/A positive positive
15 8 F ataxia, left facial palsy, bilateral weakness No III 14 N/A N/A
N/A: not available.
Fig. 1. MRI images at diagnosis and at follow up for Case 11 (A and B) and Case 1 (C, D and E)). Axial T2 Flair image showing diffuse, expansile,
and infiltrating hyperintense pontinemass at diagnosis (A), whichwas significantly decreased in size following completion of radiation therapy (B).
Axial T2W images at diagnosis (C) showed intraaxial, infiltrating, and expansile mass lesion involving center of the pons, which was decreased in
size and intensity following radiation therapy (D), but significantly increased in size associated with transtentorial ascenden herniation 5 months
later (E).
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her symptoms and a decrease in size of the tumor by MRI (Fig. 1D)
but progressed 5 months later (Fig. 1E) then died 10 months
following diagnosis.
DISCUSSION
The diagnosis of DIPG is generally based on clinical and
radiological findings as biopsy has been rarely performed. In an
earlier experience from our institution, a patient suspected of DIPG
by the radiological findings was diagnosed with a primitive
neuroectodermal tumor (PNET) based on the histology after biopsy.
Since themanagement and prognosis for PNET versus DIPG is very
different, tumor biopsy had been performed in our institution on the
majority of patients with radiological findings suggestive of DIPG.
In our cohort, there was no intraoperative complication or surgery-
related mortality. The transient new or worsening neurological
deficits observed in three patients could be due to cerebral edema
following procedures instead of surgical injuries, since all resolved
within a short period of time. In a recent French study on pediatric
DIPG, transient worsening of neurological deficit was observed in
only four out of 90 patients, suggesting stereotactic biopsy for
children with DIPG was a safe procedure [2], and similar results
were reported by others [8–11]. The overall survival in our cohort
was comparable to that reported in the literature [12], suggesting
that undergoing a biopsy did not adversely impact the outcome. The
diagnostic yield was 100% in our series, and themajority of patients
had a high-grade astrocytoma, consistent with that in the published
reports [8,9,13]. Although the histologic diagnosis in Case 1 was
consistent with a low-grade glioma, her clinical course then
imaging findings were indistinguishable from those of high-grade
glioma, therefore, sampling error or tumor heterogeneity could not
be ruled out without examining the entire tumor.
Since tumor biopsy in DIPG is rarely performed, we hope to
share our experience with the pediatric oncology community.
Whether to perform the biopsy upfront in DIPG has been an
ongoing debate, and given the small number of cases in our series,
we don’t feel any conclusion can be drawn. While it is generally
felt that biopsy is not clinically indicated for DIPG with classic
MRI findings, postmortem evaluation has revealed a histological
diagnosis of PNET in as many as 22% of patients thought to have
DIPG [6,14] in which long-term survival has been reported with a
combined modality therapy [14,15]. The relative low-risk associat-
ed with the DIPG biopsy in our experience and in the literature,
including the recent prospective experience in specialized
centers [8], suggests that biopsy is generally safe if it is performed
by skilled neurosurgeons. On the other hand, there has been no
definite treatment identified to be effective to certain group of
patients. Current census is that until we have proven that the results
of the biopsy will change the treatment and provide the direct
benefit to patients with DIPG, this procedure should be offered
only through clinical trials, or to those cases atypical in clinical
presentations or imaging findings.
REFERENCES
1. Hankinson TC, Campagna EJ, Foreman NK, et al. Interpretation of magnetic resonance images in
diffuse intrinsic pontine glioma: A survey of pediatric neurosurgeons. J Neurosurg Pediatr 2011;8:
97–102.
2. Puget S, Blauwblomme T, Grill J. Is biopsy safe in childrenwith newly diagnosed diffuse intrinsic pontine
glioma? Am Soc Clin Oncol Educ Book 2012;32:629–633.
3. Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the
diagnosis of diffuse brain stem gliomas: A report from the Children’s Cancer Group. Neurosurgery
1993;33:1026–1029; discussion 1029–1030.
4. MacDonald TJ. Diffuse intrinsic pontine glioma (DIPG): Time to biopsy again? Pediatr Blood Cancer
2012;58:487–488.
5. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3. 3 defines
clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta
Neuropathol 2012;124:439–447.
6. Angelini P, Hawkins C, Laperriere N, et al. Post mortem examinations in diffuse intrinsic pontine glioma:
Challenges and chances. J Neurooncol 2011;101:75–81.
7. Caretti V, Jansen MH, van Vuurden DG, et al. Implementation of a multi-institutional diffuse intrinsic
pontine glioma autopsy protocol and characterization of a primary cell culture. Neuropathol Appl
Neurobiol 2013;39:426–436.
8. Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse
intrinsic pontine glioma. Pediatr Blood Cancer 2012;58:489–491.
9. Cage TA, Samagh SP, Mueller S, et al. Feasibility, safety, and indications for surgical biopsy of intrinsic
brainstem tumors in children. Childs Nerv Syst 2013;29:1313–1319.
10. Pirotte BJ, Lubansu A, Massager N, et al. Results of positron emission tomography guidance and
reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem
tumors. J Neurosurg 2007;107:392–399.
11. Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children.
J Neurosurg 2007;107:1–4.
12. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed
diffuse intrinsic pontine gliomas: A report from the Children’s Oncology Group. Neuro Oncol 2011;
13:410–416.
13. Sufit A, Donson AM, Birks DK, et al. Diffuse intrinsic pontine tumors: A study of primitive
neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas. J Neurosurg Pediatr
2012;10:81–88.
14. Robison NJ, KieranMW.Diffuse intrinsic pontine glioma: A reassessment. J Neurooncol 2014;119:7–15.
15. Fangusaro J, Finlay J, Sposto R, et al. Intensive chemotherapy followed by consolidative myeloablative
chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly
diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II
experience. Pediatr Blood Cancer 2008;50:312–318.
Pediatr Blood Cancer DOI 10.1002/pbc
DIPG Biopsy Study 165
